{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:05:21Z","timestamp":1750478721900,"version":"3.41.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.medcli.2025.106917","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:12:43Z","timestamp":1744362763000},"page":"106917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leucemia aguda de linaje ambiguo: diagn\u00f3stico, pron\u00f3stico y tratamiento"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-5716","authenticated-orcid":false,"given":"Anna","family":"Torrent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor","family":"Botafogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.106917_bib0295","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: Clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood."},{"year":"2017","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","key":"10.1016\/j.medcli.2025.106917_bib0300"},{"key":"10.1016\/j.medcli.2025.106917_bib0305","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2014-10-551465","article-title":"How I treat mixed-phenotype acute leukemia","volume":"125","author":"Wolach","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0310","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.leukres.2015.03.012","article-title":"Survival of patients with mixed phenotype acute leukemias: A large population-based study","volume":"39","author":"Shi","year":"2015","journal-title":"Leuk Res."},{"key":"10.1016\/j.medcli.2025.106917_bib0315","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcp\/aqac070","article-title":"How I diagnose acute leukemia of ambiguous lineage","volume":"158","author":"Weinberg","year":"2022","journal-title":"Am J Clin Pathol."},{"key":"10.1016\/j.medcli.2025.106917_bib0320","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia."},{"year":"2008","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","key":"10.1016\/j.medcli.2025.106917_bib0325"},{"key":"10.1016\/j.medcli.2025.106917_bib0330","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0335","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","article-title":"The genetic basis and cell of origin of mixed phenotype acute leukaemia","volume":"562","author":"Alexander","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.medcli.2025.106917_bib0340","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MOH.0000000000000322","article-title":"Mixed-phenotype acute leukemia: Current challenges in diagnosis and therapy","volume":"24","author":"Wolach","year":"2017","journal-title":"Curr Opin Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0345","first-page":"2275","article-title":"The International Consensus Classification of acute leukemias of ambiguous lineage","volume":"141","author":"Weinberg","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0350","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0355","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0360","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/sj.leu.2404848","article-title":"Acute bilineal leukemia: A rare disease with poor outcome","volume":"21","author":"Weir","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0365","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-018-04924-z","article-title":"Integrative genomic analysis of adult mixed phenotype acute leukemia delineateslineage associated molecularsubtypes","volume":"9","author":"Takahashi","year":"2018","journal-title":"Nat Commun."},{"key":"10.1016\/j.medcli.2025.106917_bib0370","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.leu.2404128","article-title":"Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system","volume":"20","author":"Owaidah","year":"2006","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0375","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.5858\/arpa.2017-0218-RA","article-title":"Mixed-phenotype acute leukemia: Diagnostic criteria and pitfalls","volume":"141","author":"Charles","year":"2017","journal-title":"Arch Pathol Lab Med."},{"key":"10.1016\/j.medcli.2025.106917_bib0380","first-page":"773","article-title":"14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia","volume":"138","author":"Di Giacomo","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0385","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","article-title":"Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia","volume":"11","author":"Montefiori","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medcli.2025.106917_bib0390","doi-asserted-by":"crossref","first-page":"101329","DOI":"10.1016\/j.beha.2021.101329","article-title":"Redefining the biological basis of lineageambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage","volume":"34","author":"Montefiori","year":"2021","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0395","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1038\/s41375-020-0761-9","article-title":"T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T\/myeloid","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0400","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-018-04924-z","article-title":"Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes","volume":"9","author":"Takahashi","year":"2018","journal-title":"Nat Commun."},{"key":"10.1016\/j.medcli.2025.106917_bib0405","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2012.064485","article-title":"Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2025.106917_bib0410","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ajh.25256","article-title":"Genomic and clinical characterization of B\/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations","volume":"93","author":"Mi","year":"2018","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0415","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bbmt.2016.02.013","article-title":"Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia","volume":"22","author":"Munker","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2025.106917_bib0420","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11912-022-01252-w","article-title":"Mixed phenotype\/lineage leukemia: Has anything changed for 2021 on diagnosis, classification, and treatment?","volume":"24","author":"B\u00e9n\u00e9","year":"2022","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.medcli.2025.106917_bib0425","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.3390\/cancers13184658","article-title":"Pediatric mixed-phenotype acute leukemia: What's new?","volume":"13","author":"Batra","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.medcli.2025.106917_bib0430","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41375-018-0058-4","article-title":"Therapy for children and adults with mixed phenotype acute leukemia: A systematic review and meta-analysis","volume":"32","author":"Maruffi","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0435","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cncr.32552","article-title":"Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force","volume":"3","author":"Orgel","year":"2020","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2025.106917_bib0440","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11912-020-01010-w","article-title":"Mixed phenotype acute leukemia: Current approaches to diagnosis and treatment","volume":"23","author":"Alexander","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.medcli.2025.106917_bib0445","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MOH.0000000000000570","article-title":"Optimal therapeutic strategies for mixed phenotype acute leukemia","volume":"27","author":"Wolach","year":"2020","journal-title":"Curr Opin Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0450","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood-2017-12-821363","article-title":"International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia","volume":"132","author":"Hrusak","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0455","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-020-04179-z","article-title":"Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: A multi-center retrospective study","volume":"99","author":"Duong","year":"2020","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0460","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-023-05162-0","volume":"102","author":"Lazzarotto","year":"2023","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0465","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12343","article-title":"Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era","volume":"93","author":"Shimizu","year":"2014","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0470","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/ajh.25873","article-title":"Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): A cancer registry analysis on real-world out come","volume":"95","author":"Qasrawi","year":"2020","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0475","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-014-1531-0","article-title":"Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropiate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status","volume":"4","author":"Kawajiri","year":"2014","journal-title":"Int J Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0480","doi-asserted-by":"crossref","first-page":"e0294","DOI":"10.1097\/MD.0000000000010294","article-title":"Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report","volume":"14","author":"Lai","year":"2018","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.medcli.2025.106917_bib0485","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3324\/haematol.2017.174441","article-title":"Mixed phenotype acute leukemia: Outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT","volume":"102","author":"Munker","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2025.106917_bib0490","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.leukres.2016.04.002","article-title":"Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone","volume":"45","author":"Tian","year":"2016","journal-title":"Leukemia Res."},{"key":"10.1016\/j.medcli.2025.106917_bib0495","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.V128.22.178.178","article-title":"Predictive value of minimal residual disease in WHO2016-defined mixed phenotype acute leukemia (MPAL)","volume":"125","author":"Orgel","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0500","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/s41375-020-0741-0","article-title":"Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: A multi-center cohort study","volume":"7","author":"Oberley","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0505","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/biomedicines10081974","article-title":"Mixed-phenotype acute leukemia: Clinical diagnosis and therapeutic strategies","volume":"10","author":"George","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.medcli.2025.106917_bib0510","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1021\/acs.jmedchem.8b00071","article-title":"Complexity of blocking bivalent protein-protein interactions: Development of a highly potent inhibidor of the menin-mixed-lineage leukemia interaction","volume":"61","author":"Borkin","year":"2018","journal-title":"J Med Chem."},{"key":"10.1016\/j.medcli.2025.106917_bib0515","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106917_bib0520","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1080\/10428194.2020.1802451","article-title":"The successful use of FLT3 inhibitors in FLT3-positive mixed phenotype acute leukemia","volume":"61","author":"Andrews","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2025.106917_bib0525","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ejh.13717","article-title":"Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series","volume":"108","author":"Tremblay","year":"2022","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0530","first-page":"e40661","article-title":"Treatment of relapsed B\/T-cell mixed phenotype acute leukemia with blinatumomab","volume":"15","author":"Abdo","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.medcli.2025.106917_bib0535","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy."},{"key":"10.1016\/j.medcli.2025.106917_bib0540","doi-asserted-by":"crossref","first-page":"637951","DOI":"10.3389\/fonc.2021.637951","article-title":"Case report: Targeting 2 antigens as a promising strategy in mixed phenotype acute leukemia: Combination of blinatumomab with gemtuzumab ozogamicin in an infant with a KMT2A-rearranged leukemia","volume":"11","author":"Brethon","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.medcli.2025.106917_bib0545","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40364-020-00216-1","article-title":"Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed\/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: A case report","volume":"8","author":"Li","year":"2020","journal-title":"Biomark Res."},{"key":"10.1016\/j.medcli.2025.106917_bib0550","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/bjh.16982","article-title":"CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease","volume":"191","author":"Kong","year":"2020","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0555","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed Bacute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2025.106917_bib0560","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-021-00239-w","article-title":"Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory\/relapse acute leukemias of ambiguous lineage, not otherwise specified","volume":"10","author":"Liu","year":"2021","journal-title":"Exp Hematol Oncol."},{"key":"10.1016\/j.medcli.2025.106917_bib0565","first-page":"8811673","article-title":"Venetoclax and decitabine for T\/myeloid mixed-phenotype acute leukemia not otherwise specified (MPALNOS)","volume":"2020","author":"Klocke","year":"2020","journal-title":"Case Rep Hematol."},{"key":"10.1016\/j.medcli.2025.106917_bib0570","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.12998\/wjcc.v11.i26.6200","article-title":"T\/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report","volume":"11","author":"Park","year":"2023","journal-title":"World J Clin Cases."},{"key":"10.1016\/j.medcli.2025.106917_bib0575","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000519882","article-title":"Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B\/myeloid mixed-phenotype acute leukemia and relapsed\/refractory acute myeloid leukemia: A report of 3 cases","volume":"67","author":"Wang","year":"2022","journal-title":"Chemotherapy."},{"key":"10.1016\/j.medcli.2025.106917_bib0580","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325001113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325001113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T17:40:00Z","timestamp":1750441200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0025775325001113"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.106917","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leucemia aguda de linaje ambiguo: diagn\u00f3stico, pron\u00f3stico y tratamiento","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.106917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106917"}}